Recently, listed companies have begun to release 2023 annual performance forecasts, and among the listed companies in Harbin, there are currently 6 companies that are expected to achieve growth in net profit in 2023, among them, Harbin Sanlian, Yuheng Pharmaceutical, Harbin Investment Co., Ltd., *ST Jinglan, Guozhong Water, etc., will achieve one to two times the growth of net profit in 2023.
Boshi said in the announcement that the company expects the performance to increase from January to December 2023, and the net profit attributable to shareholders of listed companies will be 4900 million to 57.9 billion, net profit increased by 10% to 30% year-on-year. The performance growth was mainly driven by the fulfillment of intelligent equipment orders and product delivery, as well as the orderly implementation of the company's product and service integration strategy, and the company's "intelligent manufacturing equipment" + "industrial services" business led the company's revenue and net profit attributable to shareholders of listed companies to achieve good and rapid growth year-on-year. Harbin Boshi Automation Co., Ltd. is mainly engaged in the research and development, production and sales of complete sets of petrochemical post-processing equipment, and provides customers with related services. The main products include complete sets of automatic packaging and palletizing equipment for powder and granules, complete sets of equipment for post-processing of synthetic rubber, (high temperature) furnace operation robots, automatic loading machines (intelligent freight transfer equipment), industrial waste acid, acid gas treatment and recycling technology and equipment, products and services.
Harbin Sanlian Pharmaceutical Co., Ltd. said in the announcement that the company's operating income in 2023 will be about 11800 million yuan, a year-on-year increase of about 15%; The net profit attributable to shareholders of listed companies was 68.4 million yuan to 80.4 million yuan, an increase of 1 over the same period last year26 times to 166 times. During the reporting period, the company actively responded to market demand, paid attention to policy changes, and expanded sales channels, and the company's infusion products won the bid for the centralized procurement of basic infusion in Heilongjiang Province, and injection products such as ondansetron hydrochloride injection participated in the national centralized procurement of drugs and won the bid. The sales volume and revenue of the company's bid-winning products increased year-on-year, and at the same time, the company's business department continued to strengthen cost management, and the unit cost of the corresponding bid-winning products decreased. At the same time, the increase in the subsidy received by the company in the reporting period, as well as the change in the fair value of the investment and the investment income generated by the company.
In addition, Yuheng Pharmaceutical expects the company to achieve a net profit growth of 169 times to 182 times; Harbin Investment Co., Ltd. expects to achieve net profit growth of 1about 9 times; *ST expects net profit growth of 171 times to 204 times; Guozhong Water expects to achieve net profit growth of 126 times to 139 times.
*: Harbin News Network.
Reporter: Zhou Chen.
Editor: Liu Yixuan.